Number of pages: 100 | Report Format: PDF | Published date: May 03, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
Report Attribute |
Details |
CAGR |
29.3% |
Base Year for Estimation |
2022 |
Forecast Period |
2023 to 2031 |
Historical Year |
2021 |
Segments Covered |
Type, End User, and Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global gene therapy in CNS disorder market is expected to register a revenue CAGR of 29.3% during the forecast period from 2023 to 2031.
Gene Therapy in CNS Disorder Market Fundamentals
Gene therapy is a promising approach for treating a wide range of diseases. In CNS disorders, gene therapy aims to deliver functional genes to the brain or spinal cord to replace or repair defective genes or to enhance the expression of certain genes. This approach has shown potential in preclinical studies and early-phase clinical trials for conditions such as Parkinson's disease, spinal muscular atrophy, and certain types of inherited blindness. The transfer of genes that encode therapeutic proteins, such as growth factors or enzymes, to promote neuronal growth and repair damaged tissue is another promising gene therapy approach for CNS disorders. This strategy has shown promise in treating ailments like spinal cord injury and stroke in preclinical investigations. For instance, recent clinical trials for gene therapy in CNS disorders have yielded promising outcomes, such as the recent Food and Drug Administration approval of Zolgensma, a gene therapy for spinal muscular atrophy that has demonstrated considerable improvement in motor function and survival rates in affected newborns. Gene therapy for CNS disorders is a rapidly growing field with several current trends and developments. Recent gene therapy for CNS disorders industry opportunity and developments includes using viral vectors, targeted gene editing, and non-viral delivery methods.
The research study on gene therapy in CNS disorder market overview thoroughly analyzes the market and the aspects that either help or hinder the market's growth, such as its drivers, challenges, and opportunities. The research also discusses the list of businesses that operate in this market and their efforts to establish themselves as major players through expansion plans and innovative ideas. It also emphasizes current events that support the market's revenue expansion. The research also analyses how the COVID-19 pandemic has affected society.
This report is an important tool for the industry stakeholders to gather all the information about the market, customers, and competition. The report also provides the readers with valuable insights on the segmentation, regions, market size & forecast, revenue CAGRs, and other valuable data to help make informed strategic decisions. The study compiles information gathered from industry participants and specialists across the industry value chain. The report also taps into the qualitative and quantitative assessments by industry analysts. Our reports use different methods for estimating the market size and forecast, including secondary research, surveys and interviews, and statistical modeling. With these steps, our reports provide the most accurate market data. These datasets will cumulatively provide in-depth gene therapy in CNS disorder market forecast to the industry stakeholders.
Gene Therapy in CNS Disorder Market Dynamics
Globally, the prevalence of CNS diseases such as Alzheimer's, Parkinson's, and Huntington's disease is increasing. These illnesses not only impact patients quality of life but also place a considerable strain on healthcare systems and society as a whole. As a result, effective prevention and treatment measures to address this expanding public health issue are urgently needed. To address these unmet needs with limited therapeutics options influence gene therapy in CNS disorder market dynamics regarding revenue generation.
However, delivering the therapeutic gene to the target cells in the brain or spinal cord is one of the most difficult obstacles for gene therapy in CNS disorders. Also, the long-term safety of gene therapy in CNS disorders is still being evaluated, potentially inhibiting gene therapy in CNS disorder market growth due to the lack of patient preferences.
Gene Therapy in CNS Disorder Market Ecosystem
Gene Therapy in CNS Disorder Market, by Indication
Gene Therapy in CNS Disorder Market, by Type
Gene Therapy in CNS Disorder Market, by End User
Gene Therapy in CNS Disorder Market by Indication
[45645]
Based on the indications, gene therapy in CNS disorder market is segmented into Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, motor neuron disease, multiple sclerosis, adrenoleukodystrophy & metachromatic leukodystrophy, neuropathies, and batten disease.
According to the gene therapy in CNS disorder industry analysis, Alzheimer’s disease accounted for the largest revenue share of gene therapy in CNS disorder market in 2022. Alzheimer’s disease is a gradual and irreversible neurological ailment that impairs brain function, resulting in memory loss, cognitive decline, and behavioral changes. It is the leading cause of dementia, accounting for 60-80% of cases, with an increased prevalence of Alzheimer's disease. According to the World Alzheimer Report 2021, approximately 53 million persons were living with dementia in 2020, with Alzheimer's disease accounting for 70% of all dementia cases. According to the report, the number of individuals living with dementia is expected to reach 152 million by 2050, with most cases occurring in low- and middle-income nations. Gene therapy for Alzheimer's disease is in its initial stages, preclinical studies have yielded promising results, and several gene therapy clinical trials are underway. This robust clinical pipeline of advanced and effective gene therapy provides lucrative opportunities to expand the gene therapy in CNS disorder market size.
Segmentation of the market refers to the division of the industry into subgroups based on factors such as indication, type, and end user. Market segmentation data helps businesses to understand the preferences and unique needs of different customer groups and develop targeted sales strategies. This information also helps in identifying potential gene therapy in CNS disorder market growth opportunities.
Gene Therapy in CNS Disorder Market by Region
Geographically, the gene therapy in CNS disorder market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest gene therapy in CNS disorder market share owing to the well-established regulatory framework for gene therapy, with the FDA providing clear guidelines and a fast-track approval process for gene therapies. Moreover, the increasing prevalence of CNS disorders and sufficient funds for R&D are the major factors improving the gene therapy in CNS disorder Market outlook in North America.
Based on the regions, the global gene therapy in CNS disorder market is segmented into:
Regional demarcation of the industry will provide information on geographic pockets regarding gene therapy in CNS disorder market outlook, size, share, and growth rate. This data helps businesses evaluate the expansion potential into new regional markets, understand the competitive threats across different regions, and develop localized sales and expansion strategies.
Key Components of the Report
Gene Therapy in CNS Disorder Market Competitive Landscape
Multiple companies across the globe are investing in raising awareness and new product launches, which is expected to improve gene therapy in CNS disorder market outlook. Notable market participants account for the largest portion of the global gene therapy in CNS disorder market size include PTC Therapeutics, Inc., Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, UniQure Biopharma, and others.
The market competitive landscape is performed by collecting and analyzing information about the key competitors, the present industry trends, and market dynamics. It includes information collection and analysis on factors such as products, pricing, geographic outreach, customer demographics, marketing strategies, and recent developments. Competitive landscape assessment will help businesses identify the current prevalent or potential opportunities and threats, keeping in mind the gene therapy in CNS disorder industry trends.
Gene Therapy in CNS Disorder Market Strategic Developments
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Reasons to Buy this Report
Gene therapy is a promising approach for treating many central nervous system (CNS) disorders. In CNS disorders, gene therapy intends to deliver functional genes to the central nervous system to replace or repair defective genes or to enhance the expression of certain genes.
North America will have the largest gene therapy in CNS disorder market size during the forecast period from 2023 to 2031.
The global gene therapy in CNS disorder market is expected to grow with a revenue CAGR of 29.3% during the forecast period from 2023 to 2031.
The most prominent gene therapy in the CNS disorder industry trend is developing a more effective and advanced gene therapy non-viral delivery system to improve the treatment.
The high cost of the treatment and lack of awareness of gene therapy are the major challenges hampering the growth of global gene therapy in CNS disorder market.
Increased research and development improving the pipeline for gene therapy, and raising funds to promote gene therapy manufacturing are the drivers of the global gene therapy in CNS disorder market.
Key players in the global gene therapy in CNS disorder market are Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio Inc., Biogen, Pfizer Inc., and Rapa Therapeutics.
The major strategies key market players adopt involve strategic partnerships and collaborations to expand their market reach and capabilities.
Alzheimer's Disease accounted for the highest share in the global gene therapy in CNS disorder market based on the indications.
*Insights on financial performance are subject to the availability of information in the public domain